Previous 10 | Next 10 |
TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference PR Newswire ANDOVER, Mass. , Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming ...
TransMedics Group ( NASDAQ: TMDX ) said on Thursday it has priced an upsized underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $40.00/share for expected gross proceeds to be $130M. All of the shares are being offered by TransM...
TransMedics Announces Upsize and Pricing of Public Offering of Common Stock PR Newswire ANDOVER, Mass. , Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplan...
TransMedics ( NASDAQ: TMDX ) stock slid 6.1% postmarket on Wednesday after the firm announced a proposed $100M public share offering . TMDX expects to grant underwriters a 30-day option to buy additional shares in an amount of up to 15% of the number of shares sold in...
TransMedics Announces Proposed Public Offering of Common Stock PR Newswire ANDOVER, Mass. , Aug. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for...
TransMedics came in with another solid quarterly performance with upside in revenue versus consensus. The company is at an inflection point posting a record quarter in terms of sales and gross margin of 70%. We believe investors are paying fair value for the stock at $36–$3...
TransMedics ( NASDAQ: TMDX ) stock fell ~4% Aug. 2 after the CEO noted that the company intends to be cautious in its estimates, despite having raised its FY22 revenue outlook. Q2 net loss widened to -$11.52M, compared to -$10.67M in the year ago period. However,...
Start Time: 16:30 End Time: 17:16 TransMedics Group, Inc. (TMDX) Q2 2022 Earnings Conference Call August 01, 2022, 16:30 PM ET Company Participants Waleed Hassanein - President and CEO Stephen Gordon - CFO Brian Johnston - Gilmartin Group Conference...
TransMedics Group press release ( NASDAQ: TMDX ): Q2 GAAP EPS of -$0.41 misses by $0.06 . Revenue of $20.5M (+150.0% Y/Y) beats by $4.23M . Shares -5% . TransMedics is updating full year 2022 net revenue to be in the range of $67 million to $75 million ...
TransMedics Reports Second Quarter 2022 Financial Results PR Newswire Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ANDOVER, Mass. , Aug. 1,...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...